The phase 3 ARRECTOR study (ClinicalTrials.gov Identifier: NCT05028582) was a parallel group, double-blind, vehicle-controlled study that included patients with plaque psoriasis of the scalp and ...
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ResearchAndMarkets ...
The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...
The trial also met key secondary endpoints, including a greater percentage of patients achieving a 90% improvement in Psoriasis Scalp Severity ... and Goldman Sachs have responded positively ...
Treatment for a tingling scalp will depend on the underlying cause. Some people may have recurrent or ongoing (chronic ... Dermnet NZ. Scalp folliculitis. National Psoriasis Foundation. Scalp ...